ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1501

Umbilical Cord Mesenchymal Stem Cells Inhibit The Generation Of T Follicular Helper Cell In Sjogren’s Syndrome

Rui Liu1, Min Zhou1, Dinglei Su1, Xia Li1 and Lingyun Sun2, 1Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and mesenchymal stem cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The immune suppressive properties of mesenchymal stem cells (MSC) have garnered increasing attention over past decades. Human umbilical cord-derived MSC (UC-MSC) share similar immunosuppressive functions as bone marrow-derived MSC (BM-MSC). Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by extraglandular abnormalities and overproduction of antibodies. Previous studies showed that MSC transplantation were effective both in an animal model and SS patients. However, the underlining mechanism remains largely unknown. The aim of this study is to investigate whether UC-MSC might suppress the generation of T follicular helper (Tfh) cells in SS.

Methods: The percentages of CXCR5+PD-1+CD4+ cells were analyzed by flow cytometry in peripheral blood mononuclear cells (PBMC) from SS patients and healthy controls. The correlation between frequencies of Tfh cells and levels of total IgG, anti-Ro/SSA and anti-La/SSB in SS patients were assessed. PBMC of SS patients in the presence or absence of PHA were cultured with UC-MSC supernatant or UC-MSC at a ratio of 1 to 1, 1 to 10 or 1 to 100 in a cell-to-cell contact or transwell system for 3 days. CD4+ naïve T cells were isolated from SS PBMC and then co-cultured with or without UC-MSC under Tfh-skewing condition for 2 days (for RT-PCR) or 4 days (for FACS). CD4+ T cells were isolated from SS PBMC and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) and then co-cultured with or without UC-MSC in the presence of anti-CD3/CD28 for 4 days. The percentages of CXCR5+PD-1+CD4+ T cells were tested by flow cytometry.

Results:

We showed that the circulating percentage of CXCR5+PD-1+CD4+ cells in SS patients were significantly higher than in healthy controls, and positively correlated with levels of anti-La/SSB but not with total IgG or anti-Ro/SSA. UC-MSC inhibited the generation of Tfh cells in PHA-stimulated PBMC dose-dependently in vitro. The differentiation and proliferation of Tfh cells were blocked by UC-MSC significantly and this suppression was mediated by UC-MSC-secreted soluble factors. RT-PCR showed that UC-MSC suppression of Tfh cells was dependent on indoleamine 2, 3-dioxygenase (IDO). Furthermore, UC-MSC supernatant was also able to inhibit the generation of Tfh cells in SS.

Conclusion:

These results suggest that Tfh cells may play a pathogenic role in SS. UC-MSC inhibition of Tfh cells may be a potential mechanism for the therapeutic effect of MSC in SS.


Disclosure:

R. Liu,
None;

M. Zhou,
None;

D. Su,
None;

X. Li,
None;

L. Sun,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/umbilical-cord-mesenchymal-stem-cells-inhibit-the-generation-of-t-follicular-helper-cell-in-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology